Human Bronchiectasis Rhinovirus Challenge to Define Immunopathogenesis of Exacerbation

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are: * Does viral infection with the common cold lead to an exacerbation in bronchiectasis? * Does the immune response differ to that of a healthy participant? Participants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• For healthy volunteers:

• 1\) Age 18 to 65 years.

• For bronchiectasis study subjects:

‣ Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .

⁃ For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.

Locations
Other Locations
United Kingdom
St Mary's Hospital - Imperial Clinical Respiratory Research Unit (ICRRU)
RECRUITING
London
Contact Information
Primary
Charlotte E Carter, MBChB
cecarter@ic.ac.uk
+447814752750
Backup
Aran Singanayagam, PhD
a.singanayagam@imperial.ac.uk
Time Frame
Start Date: 2024-07-24
Estimated Completion Date: 2027-10-30
Participants
Target number of participants: 54
Treatments
Other: Rhinovirus Challenge
All patients in the study will receive Rhinovirus A-16
Related Therapeutic Areas
Sponsors
Collaborators: Imperial College Healthcare NHS Trust
Leads: Imperial College London

This content was sourced from clinicaltrials.gov